Overview

* Esperion Q3 2025 total revenue grows 69% yr/yr to $87.3 mln

* Net income for Q3 missed analyst expectations

* Reached settlement with Dr. Reddy's to delay generics until 2040

Outlook

* Esperion expects sustainable profitability beginning in Q1 2026

* Company reiterates 2025 operating expenses forecast of $215 mln to $235 mln

* Esperion anticipates bempedoic acid inclusion in U.S. guidelines in early 2026

Result Drivers

* U.S. PRESCRIPTION VOLUME - Increased U.S. prescription volume and expanded payer coverage drove revenue growth

* SETTLEMENT AGREEMENT - Settlement with Dr. Reddy's prevents generic competition until 2040, supporting market leadership

* GUIDELINE INCLUSION - Bempedoic acid's inclusion in European guidelines expected to boost utilization

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $40.66

Product mln

Sales

Q3 Net Miss -$31.33 -$14.50

Income mln mln (5

Analysts

)

Q3 Miss -$9.96 -$1.53

Operatin mln mln (4

g Income Analysts

)

Q3 Basic -$0.16

EPS

Q3 $97.27

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Esperion Therapeutics Inc ( ESPR ) is $4.00, about 26.5% above its November 5 closing price of $2.94

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)